12:00 AM
Aug 19, 2013
 |  BC Week In Review  |  Company News  |  Other News

Allergan ophthalmic news

India's Intellectual Property Appellate Board (IPAB) invalidated two patents held by Allergan for ophthalmic drugs Ganfort bimatoprost/timolol and Combigan brimonidine/timolol, citing obviousness in both cases. Ganfort is a fixed-dose of 0.03% bimatoprost, a prostaglandin analog, and 0.5% timolol, a beta adrenenergic receptor inhibitor. Combigan is a combination of...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >